49 completed, 9 terminated, 9 unknown, 7 recruiting. 81 Phase 2, 13 Phase 1, 10 Phase 3.
Follow Malabsorption Syndromes: new trials by email Literature Review of Malabsorption Syndromes trials Research Report on Malabsorption Syndromes
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of TRA16 Administered Orally in Patients With Enteric Hyperoxaluria (EH). TRA16, Placebo - Enteric Hyperoxaluria | Phase 2 | Not yet recruiting | Wuhan Kangfude Urolithiasis Research Institute Co., Ltd. | 30 | 2027-03-01 | 2026-10-13 |
| A Clinical Study of FT1 in Patients With Short Bowel Syndrome FT1, Placebo - Short Bowel Syndrome, SBS | Phase 2 | Recruiting | Chongqing Peg-Bio Biopharm Co., Ltd. | 8 | 2026-08-30 | 2026-07-15 |
| Study of DONQ52 in Active Celiac Disease Placebo DONQ52, Simulated Inadvertent Gluten Exposure (SIGE) capsule, DONQ52 - Celiac Disease | Phase 2 | Recruiting | Chugai Pharmaceutical | 92 | 2025-12-16 | 2026-08-14 |
| Assess the Safety of ELGN-2112 in Preterm Infants Born Under 26 Weeks GA and IUGR Infants Born 26-32 Weeks GA ELGN-2112, Placebo - Intestinal Malabsorption | Phase 2 | Recruiting | Elgan Pharma Ltd. | 60 | 2025-10-28 | 2026-04-09 |
| Randomized, Double Blind, Placebo-controlled Phase 2 Study in Adults With Celiac Disease FB102, Placebo - Celiac Disease | Phase 2 | Recruiting | Forte Biosciences, Inc. | 100 | 2025-08-04 | 2025-11-18 |
| Safety and Efficacy of Crofelemer in Adult Patients With Short Bowel Syndrome and Intestinal Failure (SBS-IF) Without Colon-in-continuity (CIC) Crofelemer Powder for Oral Solution, Matched Placebo Powder for Oral Solution - Short Bowel Syndrome, Malabsorption Syndromes | Phase 2 | Recruiting | Napo Therapeutics, S.p.A. | 18 | 2025-05-29 | 2026-06-09 |
| A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease TEV-53408, Placebo - Celiac Disease | Phase 2 | Active not recruiting | Teva Branded Pharmaceutical Products R&D LLC | 50 | 2025-03-31 | 2026-10-09 |
| A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease Amlitelimab, Placebo, SIGE - Coeliac Disease, Celiac Disease | Phase 2 | Active not recruiting | Sanofi | 229 | 2024-08-29 | 2026-08-31 |
| Evaluating the Efficacy and Tolerability of ZED1227 in Subjects With Non-responsive Celiac Disease ZED1227 + SIGE, Placebo - Celiac Disease | Phase 2 | Recruiting | Dr. Falk Pharma GmbH | 356 | 2024-06-10 | 2026-04-02 |
| A Study of Efficacy, Safety, and Tolerability of KAN-101 in People With Celiac Disease KAN-101, Placebo - Celiac Disease, Coeliac Disease | Phase 2 | Completed | Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA | 55 | 2023-12-13 | 2025-12-18 |
| Double Blind, Placebo-controlled Trial to Establish Safety and Efficacy of Ritlecitinib in Celiac Disease Patients in Remission Ritlecitinib, Placebo, Gluten - Celiac Disease | Phase 2 | Completed | Massachusetts General Hospital | 62 | 2023-03-01 | 2026-09-15 |
| A Study to Assess the Safety of TPM502 in Adults With Celiac Disease TPM502, Placebo - Celiac Disease | Phase 2 | Completed | Topas Therapeutics GmbH | 28 | 2022-12-12 | 2025-12-03 |
| Probiotic Blend for Celiac Disease Probiotic blend, Placebo - Celiac Disease | Phase 2 | Unknown | Universidade do Extremo Sul Catarinense - Unidade Academica de Ciecias da Saude | 118 | 2022-11-17 | 2022-12-12 |
| A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in Celiac Disease (ACeD-it) Cohort 1 in Part A, Cohort 2 in Part A, Placebo: Group 1 in Part B and Part C - Celiac Disease | Phase 1 / Phase 2 | Terminated | Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA | 128 | 2022-11-15 | 2026-03-10 |
| A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet TAK-062, Simulated Inadvertent Gluten Exposure (SIGE) Gluten-Bar, TAK-062 Placebo - Celiac Disease | Phase 2 | Completed | Takeda | 153 | 2022-06-30 | 2025-08-20 |
| Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet Placebo, TAK-101, Gluten - Celiac Disease | Phase 2 | Completed | Takeda | 102 | 2022-06-23 | 2026-10-06 |
| Phase 2 Study to Assess the Safety, PK, and PD of Sonefpeglutide (HM15912) in SBS-IF Subjects HM15912 Active, Placebo - Short Bowel Syndrome | Phase 2 | Recruiting | Hanmi Pharmaceutical Company Limited | 18 | 2022-03-03 | 2026-08-12 |
| Functional Sucrase Deficiency in Short Bowel Syndrome Patients With Intestinal Failure Sucrase, Placebo - Short Gut Syndrome | Phase 2 | Terminated | University of Miami | 3 | 2022-01-31 | 2025-10-01 |
| Metabolic Balance Study of Apraglutide in Patients With Short Bowel Syndrome, Intestinal Failure (SBS-IF) and Colon-in-Continuity (CIC) Apraglutide - Short Bowel Syndrome | Phase 2 | Completed | VectivBio AG | 10 | 2021-06-14 | 2025-06-18 |
| VIBRANT Study of Vurolenatide in Adult Patients With Short Bowel Syndrome. Vurolenatide 50mg/PBO, Vurolenatide 100mg/PBO, Vurolenatide 50/50 mg - Short Bowel Syndrome | Phase 2 | Terminated | 9 Meters Biopharma, Inc. | 12 | 2021-06-14 | 2022-12-20 |
Showing 20 of 81. Sign in to see all of them.
Celiac Disease (44) · Short Bowel Syndrome (26) · Cholestasis (4) · Intestinal Failure (4) · Gastrointestinal Diseases (3) · Hyperhomocysteinemia (3) · Diarrhea (2) · Enterocolitis, Necrotizing (2) · Gastroschisis (2) · Hypertension (2) · Intestinal Atresia (2) · Intestinal Diseases (2) · Irritable Bowel Syndrome (2) · Lactose Intolerance (2)
Digestive System Diseases (77) · Intestinal Diseases (76) · Gastrointestinal Diseases (75) · Nutritional and Metabolic Diseases (58) · Metabolic Diseases (56) · Pathological Conditions, Signs and Symptoms (29) · Pathologic Processes (26) · Postoperative Complications (25) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (9) · Genetic Diseases, Inborn (7) · Metabolism, Inborn Errors (6) · Nutrition Disorders (5) · Avitaminosis (4) · Bile Duct Diseases (4)
ALV003 (6) · Glutens (5) · larazotide acetate (5) · fish oil triglycerides (3) · ASP-1 protein, Necator americanus (2) · Capsules (2) · Diet, Gluten-Free (2) · Fish Oils (2) · RP-G28 (2) · AMG-714 (1) · Amlodipine (1) · CCX282-B (1) · Colesevelam Hydrochloride (1) · Contraceptives, Oral (1) · Corn Oil (1)
9 Meters Biopharma, Inc. (7) · Alvine Pharmaceuticals Inc. (3) · Boston Children's Hospital (3) · Takeda (3) · All India Institute of Medical Sciences (2) · Amgen (2) · Elgan Pharma Ltd. (2) · Entero Therapeutics (2) · GlyPharma Therapeutics (2) · Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA (2) · Oslo University Hospital (2) · Ritter Pharmaceuticals, Inc. (2) · AGA Clinical Research Associates, LLC (1) · Alberta Children's Hospital (1) · Amarnath, Rathna, M.D. (1)
United States (39) · Canada (14) · Australia (10) · Finland (10) · Germany (6) · France (5) · Italy (5) · Netherlands (5) · Norway (5) · Poland (5) · United Kingdom (5) · Belgium (4) · Denmark (4) · New Zealand (4) · Spain (4)
Tomasz Masior (3) · Joseph Murray, MD (2) · A James M Daveson, MBBS (1) · Alberto Lanzini, MD, PhD (1) · Alessio Fasano, MD (1) · Alex Loukas, BSc Hon, PhD (UQ) (1) · Alexander Loukas, PhD (1) · Amanda Fifi, MD (1) · Andrew Clouston, MBBS (Qld) PhD (Qld) FRCPA (1) · Andrew Pascoe, B. Pharm, B.Sc, MBBS, FRACP (1) · Andrew Prentice, PhD (1) · Barbara Zanini, MD, PhD (1)
PMID 22825365, PMID 23163616, PMID 24583059, PMID 41039829, PMID 12219789, PMID 12556782, PMID 12809831, PMID 17960014, PMID 19661785, PMID 19829124, PMID 19879973, PMID 20980771, PMID 21131921, PMID 21324480, PMID 21408161, PMID 21791335, PMID 22619366, PMID 22752636, PMID 23453547, PMID 24124328, PMID 24330605, PMID 24795483, PMID 25271602, PMID 25683116, PMID 25987795, PMID 26134988, PMID 26838529, PMID 27864127, PMID 28343108, PMID 28755266, PMID 30880176, PMID 31326433, PMID 31408467, PMID 31494096, PMID 32059815, PMID 33032471, PMID 33038344, PMID 33239013, PMID 33722583, PMID 34287970, PMID 34287979, PMID 34365905, PMID 34695449, PMID 35622082, PMID 35931103, PMID 36898393, PMID 39461299, PMID 41758576, PMID 41903849, PMID 42861767
2015 (1), 2018 (1), 2023 (1), R01DK054681 (1), R01DK055850 (1), R33AT009637 (1), R44DK121606 (1), U44AI134590 (1)